Develops an injectable treatment made from pancreatic proenzymes for patients with solid tumors, including pancreatic, ovarian and colorectal cancers. Sources 10-K for FY2026, filed Sep 25, 2026 We are a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic…View ↗ PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a…View ↗
10-K for FY2026, filed Sep 25, 2026
We are a biopharmaceutical company developing a novel approach to prevent recurrence and metastasis from solid tumors by using pancreatic…View ↗
PRP is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention. PRP is a…View ↗
No revenue reported yet. Sources 10-K, filed Sep 28, 2016 View ↗
10-K, filed Sep 28, 2016
View ↗
Loading...
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
